Wendy future of retail top

Basaglar

Lilly, BI cleared to market Basaglar long-acting insulin

Lilly, BI cleared to market Basaglar long-acting insulin

INDIANAPOLIS and RIDGEFIELD, Conn. — Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals Inc. have received approval for Basaglar long-acting insulin (insulin glargine injection, 100 units/ml) in the United States. The companies said Basaglar has an identical amino acid sequence to Lantus, another U-100 insulin glargine, and is delivered via the prefilled Basaglar KwikPen. Basaglar

PP_1170x120_10-25-21